In people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before ...

Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

The report explains that Pharmac’s current funding model is a cost utility analysis (CUA), which is a subset of cost effectiveness analysis. In this, Pharmac weighs up the direct healthcare costs and ...

Chair of the Meningitis Foundation, Gerard Rushton says he fully supports MSNZ and its call for Pharmac to adopt a new funding evaluation model that considers more than just the direct healthcare ...

An overhaul of the way Pharmac decides to fund drugs for people with chronic long term diseases is needed, say health ...

The following is a summary of “Recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis,” published in the September 2024 issue of Neurology by Coerver et al. Ocrelizumab ...

The rollout of COVID and flu vaccines for older adults, care home residents and those with long term health conditions kicks off today (Thursday 3 October) as the NHS drive to protect against a ...

Anti-CD20 therapies like Ocrevus (ocrelizumab) and rituximab appear to be ineffective at slowing disability progression in people with primary progressive multiple sclerosis (PPMS), a form of the ...

The FDA has approved a new injectable form of the multiple sclerosis drug ocrelizumab for use in adults with relapsing and progressive forms of the disease. Multiple sclerosis occurs when the body ...

Hacohen reported on a UK cohort of children with MS treated with ocrelizumab, with 66 patients having more than 12 months of follow-up. Of these, only four patients had relapses, and there was no ...

THURSDAY, Sept. 26, 2024 (HealthDay News) -- The U.S. Food and Drug Administration has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) as the first and only twice-a-year, 10-minute ...

Two drugs often used against MS, rituximab and ocrelizumab, may not be effective against the primary progressive form of the illness A new four-year study found no differences in disease progression ...